Strategies for smoking cessation: What is new and what works?

Expert Review of Respiratory Medicine

Volumn 2, Issue 2, 2008, Pages 201-213

  Cummings, K Michael ^a   Mahoney, Martin C ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Health counseling; Pharmacotherapy; Smoking cessation

Indexed keywords

AMFEBUTAMONE; CANNABINOID RECEPTOR; CLONIDINE; CP 945598; CYTISINE; DOPAMINE; HYPERICUM PERFORATUM EXTRACT; NICOTINE; NICOTINE GUM; NICOTINE VACCINE; NICOTINIC RECEPTOR; NORTRIPTYLINE; PLACEBO; RIMONABANT; SEROTONIN; TABEX; TARANABANT; VARENICLINE;

CANCER RISK; CLINICAL TRIAL; DRUG ABSORPTION; DRUG APPROVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; HUMAN; MOUTH ULCER; NAUSEA; NICOTINE REPLACEMENT THERAPY; NOSE IRRITATION; PATIENT COUNSELING; RASH; REVIEW; SEDATION; SIDE EFFECT; SLEEP DISORDER; SMOKING CESSATION; THROAT IRRITATION; TOBACCO DEPENDENCE; UNSPECIFIED SIDE EFFECT; WITHDRAWAL SYNDROME; XEROSTOMIA;

EID: 47249111364     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.2.2.201     Document Type: Review

References (120)

1. US CDC. Annual smoking-attributable mortality, years of potential life lost, and economic costs - United States, 1997-2001. Morb. Mortal. Wkly Rep. 54, 625-628 (2005).
2. US CDC. The Health Consequences of Smoking: A Report of the Surgeon General. US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Atlanta, GA, USA (2004).
3. Centers for Disease Control and Prevention. Cigarette smoking among adults - United States, 2006. Morb. Mortal. Wkly Rep. 56, 1157-1161 (2007).
4. International Agency for Research on Cancer (IARC). Tobacco control reversal of risk after quitting smoking. In: Handbooks of Cancer Prevention. 11 (2007).
5. Thun M, Jemal A. How much of the decrease in cancer death rates in the United States is attributable to reductions in tobacco, smoking? Tob. Control 15, 345-347 (2006).
6. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 328, 1519-1527 (2004).
7. Anthonisen N, Skeans M, Wise R et al.; for the Lung Health Study Research Group. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann. Intern. Med. 142, 233-239 (2005).
8. Twardella D, Rothenbacher D, Hahmann H et al. The underestimated impact of smoking and smoking cessation on the risk of secondary cardiovascular disease events in patients with stable coronary heart disease: prospective cohort study. J. Am. Coll. Cardiol. 47, 887-889, (2006).
9. Day G, Blot W, Shore RE et al. Second cancers following oral and pharyngeal cancers: role of tobacco and alcohol. J. Natl Cancer Inst. 86, 131-137 (1994).
10. Williams E, Sun B, Aubry Z et al. Duration of smoking abstinence as a predictor for non small-cell lung cancer survival in women. Lung Cancer 47, 165-172 (2005).
11. Fentiman IS, Allen DS, Hamed H. Smoking and prognosis in women with breast cancer. Int. J. Clin. Pract. 59, 1051-1054 (2005).
12. Mohiuddin SM, Mooss AN, Hunter CB et al. Intensive smoking cessation intervention reduces mortality in high-risk smokers with cardiovascular disease. Chest 131, 446-452 (2007).
13. Centers for Disease Control and Prevention. Cigarette smoking among adults - United States, 2000. Morb. Mortal. Wkly Rep. 51, 642-645 (2002).
14. US CDC. The Health Consequences of Smoking: Nicotine Addiction. A Report of the Surgeon General. US Department of Health Human Services, Centers for Disease Control, Office on Smoking or Health, Rockville, MD, USA (1988).
15. West R, Sohal T. "Catastrophic" pathways to smoking cessation: findings from national survey. BMJ 322(7539), 458-460 (2006).
16. Hyland A, Borland R, Li Q et al. Core predictors for quitting from the international tobacco control policy evaluation study. Tob. Control 15(Suppl. III), 83-94 (2006).
17. Piper ME, McCarthy DE, Baker TB. Assessing tobacco dependence: a guide to measure evaluation and selection. Nicotine Tob. Res. 8, 339-351 (2006).
18. Hurt RD, Robertson CR. Prying open the door to the cigarette industry's secrets about nicotine: the Minnesota Tobacco Trial. JAMA 280, 1183-1181 (1998).
19. Megerdichian CL, Rees VW, Wayne GF, Connolly GN. Internal tobacco industry research on olfactory and trigeminal nerve response to nicotine and other smoke components. Nicotine Tob. Res. 9, 1119-1129 (2007).
20. Bansal M, Cummings KM, Hyland A, Giovino GA. Stop smoking medications: who uses them, who misuses them, and who is misinformed about them. Nicotine Tob. Res. 6(Suppl. 3), 303-310 (2004).
21. Cokkinides VE, Ward E, Jemal A, Thun J. Under-use of smoking cessation treatments. Am. J. Prev. Med. 28,119-122 (2005).
22. Fiore MC, Bailey WC, Cohen SJ et al. Treating Tobacco Use and Dependence. Clinical Practice Guideline. US Department of Health Human Services, Public Health Service, Rockville, MD, USA (2000).
23. Lancaster T, Stead LF. Physician advice for smoking cessation. Cochrane Database Syt. Rev. 4, CD000165 (2004).
24. Steinberg MB, Akinciquil A, Delnevo C et al. Gender and age disparities for smoking cessation treatment. Am. J. Prev. Med. 30, 405-412 (2006).
25. Fiore MC, Novotny TE, Pierce JP et al. Methods used to quit smoking in the United States. Do cessation programs help? JAMA 263, 2760-2765 (1990).
26. Shiffman S, Fant RV, Gitchell JG. Nicotine delivery systems: how far has technology come? Am. J. Drug Deliv. 1, 112-124 (2003).
27. Cummings KM, Hyland A. Impact of nicotine replacement therapy on smoking behavior. Ann. Rev. Public Health 26, 583-599 (2005).
28. Cummings KM, Mahoney M. Current and emerging treatment approaches for tobacco dependence. Curr. Oncol. Rep. 8, 475-483 (2006).
29. Pidoplichko VI, DeBiasi M, William JT, Dani JA. Nicotine activates and desensitizes midbrain dopamine neurons. Nature 390, 401-404 (1997).
30. Lerman C, Niaura R. Applying genetic approach to the treatment of nicotine dependence. Oncogene 21, 7412-7420 (2002).
31. Perkins KA, Grobe JE, Fonte C et al. Chronic and acute tolerance to subjective, behavioral and cardiovascular effects of nicotine in humans. J. Pharmacol. Exp. Ther. 270, 628-638 (1994).
32. Damaj MI, Welch SP, Martin BR. Characterization and modulation of acute tolerance to nicotine in mice. J. Pharmacol. Exp. Ther. 277, 454-461 (1996).
33. Slemmer JE, Martin BR, Damaj MI. Buproprion is a nicotinic antagonist. J. Pharmacol. Exp. Ther. 295, 321-327 (2000).
34. Lerman C, Niaura R, Collins BN et al. Effect of bupropion on depression symptoms in a smoking cessation clinical trial. Psychol. Addict. Behav. 18, 362-366 (2004).
35. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst. Rev. 1, CD000031 (2007).
36. Foulds J. The neurobiological basis fbr partial agonist treatment of nicotine dependence: varenicline. Int. J. Clin. Pract. 60, 571-576 (2006).
37. Gonzales D, Rennard SI, Nides M et al. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-rclease bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 296, 47-55 (2006).
38. Jorenby DE, Hays JT, Rigotti NA et al. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 296, 56-63 (2006).
39. Tonstad S, Tonnesen P, Hajek P et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 296, 64-71 (2006).
40. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst. Rev. 1, CD006103 (2007).
41. Brunnhuber K, Cummings KM, Feit S, Sherman S, Woodcock J. Putting evidence into practice: smoking cessation. BMJ Clinical Evidence. BMJ Publishing Group Limited (2007).
42. Silagy C, Lancaster T, Stead L et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst. Rev. 3, CD000146 (2004).
43. Etter J-F, Stapleton JA. Nicotine replacement therapy for long-term smoking cessation: a meta-analysis. Tob. Control 15, 280-285 (2006).
44. Yudkin PL, Jones L, Lancaster T et al. Which smokers are helped to give up smoking using transdermal nicotine patches? Results from a randomized, double-blind, placebo-controlled trial. Br. J. Gen. Pract. 46, 145-148, (1996).
45. Benowitz NL. Nicotine Safety and Toxicity. New York. Oxford University Press, UK (1998).
46. Benowitz NL, Gourlay SG. Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy. J. Am. Coll. Cardiol. 29, 1422-1431 (1997).
47. Mahmarian JJ, Moye LA, Nasser GA et al. Nicotine patch therapy in smoking cessation reduces the extent of exercise-induced myocardial ischemia. J. Am. Coll. Cardiol. 30, 125-130 (1997).
48. Coleman T. Recommendations for use of pharmacological smoking cessation strategies in pregnant women. CNS Drugs 21, 983-993 (2007).
49. Hecht SS, Hochalter JB, Villalta PW, Murphy SE. 2′-hydroxylation of nicotine by cytochrome P450 2A6 and human liver microsomes: formation of a lung carcinogen precursor. Proc. Natl Acad. Sci. USA 97, 12493-12497 (2000).
50. Cooke JP. Angiogenesis and the role of the endothelial nicotinic acetylcholine receptor Life Sci. 80, 2347-2351 (2007).
51. Heeschen C, Jang JJ, Weis M et al. Nicotine stimulates agiogenesis and promotes tumor growth and atherosclerosis. Nat. Med. 7, 833-839 (2001).
52. Zevin S, Benowtitz NL. Drug interactions with tobacco smoking. An update. Clin. Pharmacokinet. 36, 425-438 (1999).
53. Shiffman S, Khayrallah M, Nowak R. Efficacy of the nicotine patch for relief of craving and withdrawal 7-10 weeks after cessation. Nicotine Tob. Res. 2, 371-378 (2000).
54. Shifman S, Patten C, Gwaltney C et al. Natural history of nicotine withdrawal. Addiction 101, 1822-1832 (2006).
55. Shiffman S. Use of more nicotine lozenges leads to better success in quitting smoking. Addiction 102, 809-814 (2007).
56. Stapleton JA, Russell MAH, Feyerabend C et al. Dose effects and predictors of outcome in a randomized trial of transdermal nicotine patches in general practice. Addiction 90, 31-42 (1995).
57. Tonnesen P, Paoletti P, Gustavsson G et al. Higher dosage nicotine patches increase one-year smoking cessation fates: results from the European CEASE trial. Eur. Resp. J. 13, 238-245 (1999).
58. Cummings KM, Hyland A, Fix B et al. Free nicotine patch giveaway program 12-month follow-up of participants. Am. J. Prev. Med. 31, 181-184 (2006).
59. Kozlowski LT, Giovino GA, Edwards B et al. Advice on using over-the-counter nicotine replacement therapy-patch, gum, or lozenge-to quit smoking. Addictive Beh. 32, 2140-2150 (2007).
60. Date LC, Hurt RD, Offord KP, Lawson GM, Croghan IT, Schroeder DR. Highdose nicotine patch therapy. Percentage of replacement and smoking cessation. JAMA 274, 135-138 (1995).
61. Benowitz N, Jacob P III, Lessov C, Swan GE, Tyndale RF. CYP2A6 genotype alters the metabolism and disposition kinetics of nicotine. Clin. Pharmacol. Ther. 80, 457-467 (2006).
62. Sweeney CT, Fant RV, Fagerstrom KO et al. Combination nicotine replacement therapy for smoking cessation: rationale, efficacy and tolerability. CNS Drugs 15, 453-467 (2001).
63. Bohadana A, Nilsson F, Rasmussen T, Martinet Y. Nicotine inhaler and nicotine patch as combination therapy for smoking cessation: a randomized, double-blind, placebo-controlled trial. Arch. Intern. Med, 160, 3128-3134 (2000).
64. Schuurmans MM, Diacon AH, Van Biljon X, Bollinger CT. Effect of pretreatment with nicotine patch on withdrawal symptoms and abstinence rates in smokers subsequently quitting with the nicotine patch: a randomized controlled trial. Addiction 99, 634-640 (2004).
65. Rose JE, Behn FM, Westman EC, Kukovich P. Precessation treatment with nicotine skin patch facilitates smoking cessation. Nicotine Tob. Res. 8, 89-101 (2006).
66. Bullen C, Whittaker R, Walker N, Wallace-Bell M. Pre-quitting nicotine replacement therapy: findings from a pilot study. Tob. Induced Dis. 3, 35-40 (2006).
67. Rezaishiraz, Hyland A, Mahoney MC, O'Connor RJ, Cummings KM. Treating smokers before quit date: can nicotine patches and denicotinized cigarettes help smokers quit? Nicotine Tob. Res. 9, 1139-1146 (2007).
68. Warner C, Shoaib M. How does bupropion work as a smoking cessation aid? Addict. Biol. 10, 219-231 (2005).
69. Rigotti NA, Thorndike AN, Regan S et al. Bupropion for smokers hospitalized for acute cardiovascular disease. Am. J. Med. 119, 1080-1087 (2006).
70. Zyban. Montvale, NJ. Thomson PDR 61, 1644-1650 (2007).
71. Hurt RD, Wolter TD, Rigotti N et al. Bupropion for pharmacologic relapse: predictors of outcome. Addict. Behav. 27, 493-507 (2002).
72. Chantix. Montvale, NJ. Thomson PDR 61, 2517-2521 (2007).
73. Stapleton JA, Watson L. Spirling LI et al. Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction 103, 146-154 (2008).
74. West R, Baker CL, Cappelleri JC, Bushmakin AG. Effect of varenicline and bupriopion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. Psychopharmacology 184, 619-627 (2007).
75. Mahoney MC, Cummings KM. Special report: FDA's varenicline update. Cortlandt Forum 8 January (2008).
76. Gourlay SG, Stead LF, Benowitz NL. Clonidine for smoking cessation. Cochrane Database Syst. Rev. 3, CD000058 (2004).
77. Frishman WH, Mitta W, Kupersmith A et al. Nicotine and non-nicotine smoking cessation pharmacotherapies. Cardiol. Rev. 14, 57-73 (2006).
78. Wagena EJ, Knipschild P, Zeegers MP. Should nortriptyline be used as a first line aid to help smokers quit? Results from a systematic review and meta-analysis. Addiction 100, 317-325 (2005).
79. Haggsträm FM, Chatkin JM, Sussenbach-Vaz E et al. A controlled trial of nortriptyline, sustained-release bupropion and placebo for smoking cessation: preliminary results. Pulm. Pharmacol. Therapeut. 19, 205-209 (2006).
80. Zatonski W, Cedzynska M, Piotr Tutka P, West R. An uncontrolled trial of cytisine (Tabex) for smoking cessation. Tob. Control 15, 481-484 (2006).
81. Etter J-F. Cytisine for smoking cessation: a literature review and a meta-analysis. Arch. Intern. Med. 166, 1553-1559 (2006).
82. Lawvere S, Mahoney MC, Cummings KM et al. A Phase II study of St. Johns Wort for smoking cessation. Complement. Ther. Med. 14, 175-184 (2006).
83. Barnes J, Barber N, Wheatley D, Williamson EM. A pilot randomised, open, uncontrolled, clinical study of two dosages of St. John's Wort ( Hypericum perforatum) herb extract (LI-160) as an aid to motivational/behavioural support in smoking cessation. Planta Med. 72, e106-e114 (2006).
84. Stead LF, Hughes JR. Lobeline for smoking cessation. Cochrane Database Syst. Rev. 3, CD000124 (1997).
85. Lancaster T, Stead LF. Silver acetate for smoking cessation. Cochrane Database Systs. Rev. 3, CD000191 (1997).
86. Biberman R, Neumann R, Katzir I et al. A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation. Addiction 98, 1403-1407 (2003).
87. George TP, Vessicchio JC, Termine A et al. A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation. Biol. Pychiatry 53, 136-143 (2003).
88. Hughes JR, Stead LF, Lancaster T. Anxiolytics for smoking cessation. Cochrane Database Syst. Rev. 4, CD002849-(2000).
89. David S, Lancaster T, Stead LF et al. Opioid antagonists for smoking cessation. Cochrane Database Syst. Rev. 4, CD003086 (2006).
90. King A, DeWit H, Riley RC et al. Efficacy of naltrexone in smoking cessation: a preliminary study and an examination of sex differences. Nicotine Tob. Res. 8, 671-682 (2006).
91. O'Malley SS, Cooney JL, Krishnan-Sarin S et al. A controlled trial of naltrexone augmentation of nicotine replacement therapy for smoking cessation. Arch. Intern. Med. 166, 667-674 (2006).
92. Abbot NC, Stead LF, White AR et al. Hypnotherapy for smoking cessation. Cochrane Database Syst. Rev. 2, CD001008 (1998).
93. White AR, Rampes H, Campbell JL. Acupuncture and related interventions for smoking cessation. Cochrane Database Syst. Rev. 1, CD000009 (2006).
94. Taylor AH, Ussher MH, Faulkner G. The acute effects of exercise on cigarette cravings, withdrawal symptoms, affect and smoking behavior: a systematic review. Addiction 102, 534-543 (2007).
95. Despres JP, Golay A, Sjostrom, et al.; for the Rimonabant in Obesity Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med. 353, 2121-2134 (2005).
96. Pi-Sunyer FX, Aronne LJ, Heshmati HM et al. for the Rimonabant in Obesity North America Study Group. Effect of rimonabant, a cannabinoid receptor blocker, on weight and cardio-metabolic risk factors in overweight or obese patients: RIO North America: a randomized controlled trial. JAMA 295, 761-775 (2006).
97. Cahill K, Ussher M. Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Cochrane Database Syst. Rev. 4, CD005353 (2007).
98. Hieda Y, Keyler DE, VanDeVoort JT et al. Immunization of rats reduces nicotine distribution to brain. Psychopharmacology 143, 150-157 (1999).
99. Hatsukami DK, Rennard S, Jorenby D et al. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin. Pharm. Ther. 78, 456-467 (2005).
100. Maurer P, Bachmann MF. Therapeutic vaccines for nicotine dependence. Curr. Opin. Mol. Ther. 8, 11-16 (2006).
101. Benowitz NL, Henningfield JE. Establishing a nicotine threshold for addiction. N. Engl. J. Med. 331, 123-125 (1994).
102. Rose JE. Nicotine and non-nicotine factors in cigarette addiction. Psychopharmacology 184, 274-285 (2006).
103. Brauer LH, Behm, FM, Lane JD et al. Individual differences in smoking reward from denicotinized cigarettes. Nicotine Tob. Res. 3, 10-19 (2001).
104. Benowitz NL, Jacob P III, Herrera B. Nicotine intake and dosese response when smoking reduced-nicotine content cigarettes. Clin. Pharm. Ther. 80, 703-714, (2006).
105. Benowitz NL, Hall SM, Stewart S et al. Nicotine and carcinogen exposure with smoking of progressively reduced nicotine content cigarette. Cancer Epidemiol. Biomarkers Prev. 16, 1-7 (2007).
106. Institute of Medicine (IOM). Ending the Tobacco Problem: A Blurprint for the Nation. The National Academic Press, Washington, DC, USA (2007).
107. Royal College of Physicians. Harm reduction in nicotine addiction: helping people who can't quit. A report by the Tobacco Advisory Group of the Royal College of Physicians. RCP, London, UK (2007).
108. Bize R, Burnand B, Mueller Y, Cornuz J. Effectiveness of biomedical risk assessment as an aid for smoking cessation: a systematic review. Tob. Control 16, 151-156 (2007).
109. Jaen CJ, McIlvain H, Pol L et al. Tailoring tobacco counseling to the competing demands in the clinical encounter. J. Fam. Pract. 50, 859-863 (2001).
110. Schroeder SA. What to do with a patient who smokes. JAMA 294, 482-487 (2005).
111. Pohlig C. Smoking cessation counseling: a practice management perspective. Chest 130, 1231-1233 (2006).
112. Theobald M, Jaén CR. An update on tobacco cessation reimbursement. Fam. Pract. Manag. 13, 75-78 (2006).
113. Halpin HA, McMenamin SB, Celia CA et al. State Medicaid coverage for tobacco-dependence treatments - United States, 2006. Morb. Mortal. Wkly Rep. 57, 117-122 (2008).
114. Orleans CT, Woolf SH, Rothernich SF et al. The top priority: building a better system for tobacco-cessation counseling. Am. J. Prev. Med. 31, 103-106 (2006).
115. Johnstone EC, Yudkin PL, Hey K et al. Genetic variation in dopaminergic pathways and short term effectiveness of the nicotine patch. Pharmacogenetics 14, 83-90 (2004).
116. Malaiyandi V, Lerman C, Benowitz NL et al. impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. Mol. Psychiatry 11, 400-409 (2006).
117. McClernon JF, Hiott FB, Liu J et al. Selectively reduced responses to smoking cues in amygdala following extinction-based smoking cessation: results of a preliminary functional magnetic resonance imaging study. Addiction Biol. 12, 503-512 (2007).
118. Rose JE. Multiple brain pathways and receptors underlying tobacco addiction. Biochem. Pharmacol. 74, 1263-1270 (2007).
119. Fiore M, Croyle R, Curry S et al. Preventing 3 million premature deaths and helping 5 million smokers quit: a national action plan for tobacco cessation. Am. J. Pub. Health 94, 205-210 (2004).
120. US CDC. The Health Benefits of Smoking Cessation. US Department of Health and Human Services, Public Health Service, Centers for Disease Control, Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. DHHS Publication No. (CDC) 90-8416, (1990).